Lesley Calhoun - Global Blood President
| GBTDelisted Stock | USD 68.49 0.00 0.00% |
President
Ms. Lesley Ann Calhoun serves as Principal Accounting Officer Vice President Finance of the Company. She has served as the Vice President Finance of the Company since August 2016. Ms. Calhoun previously served as vice president finance at Hyperion Therapeutics Inc. a commercial pharmaceutical company from January 2013 to September 2015 which was acquired by Horizon Pharma plc a biopharmaceutical company in May 2015. Prior to Horizon Pharma Ms. Calhoun served as senior director of finance and corporate controller at Theravance Inc. a biopharmaceutical company from August 2005 to January 2013. Prior to Theravance Ms. Calhoun held various senior finance positions of increasing responsibility where she oversaw all aspects of finance and accounting operations for U.S. and multinational publiclytraded and preIPO stage technology companies and in the biopharmaceutical industry. Earlier in her career Ms. Calhoun was a member of the audit practice of Deloitte Touche LLP from 1989 to 2001 since 2016.
| Age | 49 |
| Tenure | 8 years |
| Phone | 650 741-7700 |
| Web | www.globalbloodtx.com |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Clinton Haris | Entegris | 52 | |
| Raj Talluri | Micron Technology | N/A | |
| Megan Faust | Amkor Technology | 50 | |
| Anand Jayapalan | Micron Technology | N/A | |
| Jeff VerHeul | Micron Technology | N/A | |
| Raja Koduri | Advanced Micro Devices | 46 | |
| Werner Gebhardt | Vishay Intertechnology | 60 | |
| Michael Bokan | Micron Technology | 62 | |
| Sumit Sadana | Micron Technology | 55 | |
| Mike Rayfield | Advanced Micro Devices | N/A | |
| Giel Rutten | Amkor Technology | 67 | |
| Darren Grasby | Advanced Micro Devices | 48 | |
| Choon Lee | Amkor Technology | 55 | |
| Vincent Keenan | Amkor Technology | N/A | |
| Mark Rogers | Amkor Technology | 58 | |
| Corey Rucci | Entegris | 64 | |
| James Anderson | Advanced Micro Devices | 45 | |
| John Murphy | Entegris | 63 | |
| Stuart Tison | Entegris | 54 | |
| Mike Bokan | Micron Technology | N/A | |
| Sandeep Chennakeshu | Advanced Micro Devices | 59 | |
Management Performance
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
| Michael Bonney, Director | ||
| Stephanie Yao, IR Contact Officer | ||
| Myesha Lacy, IR Contact Officer | ||
| Mark Perry, Independent Director | ||
| Jeffrey Farrow, CFO | ||
| Myesha Edwards, IR Contact Officer | ||
| Philip Pizzo, Director | ||
| Glenn Pierce, Director | ||
| Willie Brown, Independent Director | ||
| Wendy Yarno, Director | ||
| Kevin Starr, Director | ||
| Hing Sham, Senior Vice President - Chemistry | ||
| Scott Morrison, Director | ||
| Deval Patrick, Independent Director | ||
| Tricia Suvari, Chief Legal Officer | ||
| Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
| David Johnson, Chief Commercial Officer | ||
| Charles Homcy, Director | ||
| Dawn Svoronos, Director | ||
| Ted Love, President CEO, Director | ||
| Eleanor Ramos, Chief Medical Officer | ||
| John Schembri, Vice President of Finance and Administration | ||
| Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 | |||
| Profit Margin | (146.82) % | |||
| Operating Margin | (137.33) % | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 64.45 M | |||
| Shares Owned By Insiders | 2.72 % | |||
| Shares Owned By Institutions | 97.28 % | |||
| Number Of Shares Shorted | 9.23 M | |||
| Price To Earning | (13.97) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Global Blood in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Global Blood's short interest history, or implied volatility extrapolated from Global Blood options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |